Biotechs' Autonomy Threatened, Area Executives Say Regulations, Lack of New Drugs Raise Stakes
Boston Globe -- Major biotechnology companies, long a staple of the Boston area’s economy, are finding it harder to remain independent. Speaking a week after the sale of Genzyme Corp. left the state’s top biotech firm in the hands of a French buyer, executives at the BD Biotech Conference in Boston yesterday said the pressure to merge is being driven by an unforgiving regulatory environment and the failure of the world’s largest pharmaceutical companies to develop new drugs.